首页 > 最新文献

Indian Journal of Hematology and Blood Transfusion最新文献

英文 中文
Study of the Frequency and Specificity of Red Cell Antibodies in Patients with Hemoglobinopathies. 血红蛋白病患者红细胞抗体的频率和特异性研究。
IF 0.9 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-10-01 Epub Date: 2023-04-17 DOI: 10.1007/s12288-023-01651-4
Manal M Wilson, Manal M W El Masry, Mona Kamal El-Ghamrawy, Nessma Abd El-Hadi, Amany A Abou-Elalla

Patients with thalassemia and sickle cell disease (SCD) require blood transfusions as part of their supportive care. However, one of the most serious side effects of this treatment is the risk of red cell alloimmunization. The goal of this study was to assess the prevalence and Specificity of red cell alloimmunization in Egyptian thalassemia and sickle cell anaemia patients. This study included 200 multi transfused Egyptian patients, one hundred and forty patients with transfusion dependent thalassaemia and sixty patients with sickle cell anaemia, who were attending the Paediatric Children Hospital-Cairo University at the period from March 2019 to October 2019. Alloantibody identification was made by Diamed- ID microtyping system. In the studied groups both thalassemia and sickle patients, the prevalence of alloimmunization was 22/200 (11%) patients. The two most often alloantibodies were, antibodies against Kell antigen (37%) and against E antigen (30%). The prevalence of alloimmunization was more in females in comparison to males, but it did not reach statistical significance and patients with thalassemia major had higher alloimmunization rates than other studied groups but was not statistically significant. In the D negative patients in the research group, alloimmunization demonstrated a statistically significant difference (p = 0.01). Age, gender, age of transfusion onset and splenectomy were not contributing factors to the antibody presence in the group of patients being investigated. Before receiving blood transfusions, extended red blood cell phenotyping should be thought of as a crucial procedure for hemoglobinopathies patients who would likely have several transfusions. It is advised that haemoglobinopathies patients in Egypt be checked through phenotyping of RBC units for Kell and all Rh antigens to be phenotyped before starting transfusion in these patients which is also standard of care for these patients presently.

地中海贫血和镰状细胞病(SCD)患者需要输血作为支持性护理的一部分。然而,这种治疗最严重的副作用之一是红细胞同种免疫的风险。本研究的目的是评估埃及地中海贫血和镰状细胞贫血症患者红细胞同种免疫的流行率和特异性。这项研究包括200名多次输血的埃及患者、140名输血依赖性地中海贫血患者和60名镰状细胞贫血患者,他们在2019年3月至2019年10月期间在开罗大学儿科儿童医院就诊。用Diamed-ID微量分型系统进行同种抗体鉴定。在地中海贫血和镰状细胞病患者的研究组中,异基因免疫的患病率为22/200(11%)。两种最常见的同种异体抗体是针对Kell抗原的抗体(37%)和针对E抗原的抗体。与男性相比,女性的同种免疫患病率更高,但没有达到统计学意义,严重地中海贫血患者的同种免疫率高于其他研究组,但没有统计学意义。在研究组的D阴性患者中,同种免疫显示出统计学上显著的差异(p = 0.01)。年龄、性别、输血开始年龄和脾切除术不是导致被调查患者中抗体存在的因素。在接受输血之前,延长红细胞表型应被视为血红蛋白病患者的一项关键程序,这些患者可能需要多次输血。建议埃及的血红蛋白病患者在开始输血前,通过红细胞单位的Kell和所有Rh抗原的表型检查,这也是目前对这些患者的标准护理。
{"title":"Study of the Frequency and Specificity of Red Cell Antibodies in Patients with Hemoglobinopathies.","authors":"Manal M Wilson,&nbsp;Manal M W El Masry,&nbsp;Mona Kamal El-Ghamrawy,&nbsp;Nessma Abd El-Hadi,&nbsp;Amany A Abou-Elalla","doi":"10.1007/s12288-023-01651-4","DOIUrl":"10.1007/s12288-023-01651-4","url":null,"abstract":"<p><p>Patients with thalassemia and sickle cell disease (SCD) require blood transfusions as part of their supportive care. However, one of the most serious side effects of this treatment is the risk of red cell alloimmunization. The goal of this study was to assess the prevalence and Specificity of red cell alloimmunization in Egyptian thalassemia and sickle cell anaemia patients. This study included 200 multi transfused Egyptian patients, one hundred and forty patients with transfusion dependent thalassaemia and sixty patients with sickle cell anaemia, who were attending the Paediatric Children Hospital-Cairo University at the period from March 2019 to October 2019. Alloantibody identification was made by Diamed- ID microtyping system. In the studied groups both thalassemia and sickle patients, the prevalence of alloimmunization was 22/200 (11%) patients. The two most often alloantibodies were, antibodies against Kell antigen (37%) and against E antigen (30%). The prevalence of alloimmunization was more in females in comparison to males, but it did not reach statistical significance and patients with thalassemia major had higher alloimmunization rates than other studied groups but was not statistically significant. In the D negative patients in the research group, alloimmunization demonstrated a statistically significant difference (<i>p</i> = 0.01). Age, gender, age of transfusion onset and splenectomy were not contributing factors to the antibody presence in the group of patients being investigated. Before receiving blood transfusions, extended red blood cell phenotyping should be thought of as a crucial procedure for hemoglobinopathies patients who would likely have several transfusions. It is advised that haemoglobinopathies patients in Egypt be checked through phenotyping of RBC units for Kell and all Rh antigens to be phenotyped before starting transfusion in these patients which is also standard of care for these patients presently.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"39 4","pages":"579-585"},"PeriodicalIF":0.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41174343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of HbA2 Using High Performance Liquid Chromatography Versus Haemoglobin Capillary Zone Electrophoresis. 高效液相色谱法与血红蛋白毛细管区带电泳法测定HbA2的比较。
IF 0.7 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-10-01 Epub Date: 2023-06-08 DOI: 10.1007/s12288-023-01648-z
Gurpreet Kaur, Seema Tyagi, Tulika Seth, Manoranjan Mahapatra, Ganesh Kumar Viswananthan, Jasmita Dass, Rama Hariharan, Arijit Sen

Thalassemia is among the most common hereditary disorders in the world. Approximately 5% of the world's population are carriers of hemoglobinopathies, and 2.9% are carriers of beta thalassemia. Haemoglobin A2 (HbA2) constitutes less than 3% of the total hemoglobin (Hb) in adults, and the determination of Hb A2 levels is important to diagnose the beta thalassemia trait (BTT). In some cases, the level of HbA2 is not typically elevated, and some difficulties may arise in making the diagnosis. Cation exchange high-performance liquid chromatography (HPLC) and HbCZE (haemoglobin capillary zone electrophoresis) are considered acceptable methods to diagnose BTT, but these vary in their accuracy and cut-offs. In this study, we attempted to compare HbA2 values using two methods, HPLC and HbCZE, in 536 whole blood samples sent by physician-ordered hemoglobinopathy screening over two years. This included antenatal women, patients with anemia not responding to iron, and cases of familial screening where either a child or a sibling had been diagnosed with hemoglobinopathy or thalassemia. The performance characteristics of both machines were compared for the detection of the 5 most common hemoglobin variants: Hb A, HbF, HbS, Hb C, and HbE. On comparing the HbA2 values, the HPLC showed higher values for HbA2 as compared to HbCZE, while the HbF and HbS measurement agreement was good between both methods. Normal ranges and mean normal values of HbA2 differ between different methods and different manufacturers; hence, each institute using these machines should validate its cutoffs.

地中海贫血是世界上最常见的遗传性疾病之一。世界上大约5%的人口是血红蛋白病携带者,2.9%是β地中海贫血携带者。血红蛋白A2(HbA2)占成人总血红蛋白(Hb)的比例不到3%,Hb A2水平的测定对诊断β地中海贫血(BTT)很重要。在某些情况下,HbA2水平通常不会升高,并且在进行诊断时可能会出现一些困难。阳离子交换高效液相色谱(HPLC)和血红蛋白毛细管区带电泳(HbCZE)被认为是诊断BTT的可接受方法,但它们的准确性和截止值各不相同。在这项研究中,我们试图使用HPLC和HbCZE两种方法,在两年内通过医生下令的血红蛋白病筛查发送的536份全血样本中比较HbA2值。这包括产前妇女、对铁没有反应的贫血患者,以及儿童或兄弟姐妹被诊断为血红蛋白病或地中海贫血的家庭筛查病例。比较了两种机器的性能特征,以检测5种最常见的血红蛋白变体:Hb A、HbF、HbS、Hb C和HbE。在比较HbA2值时,与HbCZE相比,HPLC显示出更高的HbA2值,而两种方法之间的HbF和HbS测量一致性良好。HbA2的正常范围和平均正常值在不同的方法和不同的制造商之间不同;因此,每个使用这些机器的机构都应该验证其截止值。
{"title":"Comparison of HbA2 Using High Performance Liquid Chromatography Versus Haemoglobin Capillary Zone Electrophoresis.","authors":"Gurpreet Kaur, Seema Tyagi, Tulika Seth, Manoranjan Mahapatra, Ganesh Kumar Viswananthan, Jasmita Dass, Rama Hariharan, Arijit Sen","doi":"10.1007/s12288-023-01648-z","DOIUrl":"10.1007/s12288-023-01648-z","url":null,"abstract":"<p><p>Thalassemia is among the most common hereditary disorders in the world. Approximately 5% of the world's population are carriers of hemoglobinopathies, and 2.9% are carriers of beta thalassemia. Haemoglobin A2 (HbA2) constitutes less than 3% of the total hemoglobin (Hb) in adults, and the determination of Hb A2 levels is important to diagnose the beta thalassemia trait (BTT). In some cases, the level of HbA2 is not typically elevated, and some difficulties may arise in making the diagnosis. Cation exchange high-performance liquid chromatography (HPLC) and HbCZE (haemoglobin capillary zone electrophoresis) are considered acceptable methods to diagnose BTT, but these vary in their accuracy and cut-offs. In this study, we attempted to compare HbA2 values using two methods, HPLC and HbCZE, in 536 whole blood samples sent by physician-ordered hemoglobinopathy screening over two years. This included antenatal women, patients with anemia not responding to iron, and cases of familial screening where either a child or a sibling had been diagnosed with hemoglobinopathy or thalassemia. The performance characteristics of both machines were compared for the detection of the 5 most common hemoglobin variants: Hb A, HbF, HbS, Hb C, and HbE. On comparing the HbA2 values, the HPLC showed higher values for HbA2 as compared to HbCZE, while the HbF and HbS measurement agreement was good between both methods. Normal ranges and mean normal values of HbA2 differ between different methods and different manufacturers; hence, each institute using these machines should validate its cutoffs.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"39 4","pages":"572-578"},"PeriodicalIF":0.7,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41140423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comparative Analysis of Early T-Cell Precursor Lymphoblastic Leukemia/Lymphoma (ETP-ALL/LBL) and Non-ETP-ALL/LBL in a Tertiary Cancer Care Center Based in Western India. 印度西部一家三级癌症护理中心早期T细胞前体淋巴母细胞白血病/淋巴瘤(ETP-ALL/LBL)和非-ETP-ALL/LBL的比较分析。
IF 0.7 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-10-01 Epub Date: 2023-01-12 DOI: 10.1007/s12288-023-01627-4
Anurag Saha, Beena Brahmbhatt, Varnika Rai, Sneha Kakoty, Jyoti Sawhney

Early T-cell precursor lymphoblastic leukemia (ETP-ALL) has a unique immunophenotype with very early T-cell differentiation. The current study summarises the distinct clinicopathological aspects of ETP-ALL and compares them with non-ETP-ALL. Twenty-nine ETP-ALL and 191 non-ETP-ALL cases were retrieved between 2018 and 2021. A P value was determined for each of the patient charaterisics (Table 1) to see for any significant relationship (P < 0.05) with ETP-ALL versus non-ETP-ALL. Kaplan-Meier log rank test was applied to look for any significant differences in OS for both the ALLs. ETP-ALL had an incidence of 12.6% out of total T-Acute lymphoblastic leukemia (T-ALL/LBL) in the past 3-years. Compared to non-ETP-ALL, ETP-ALL cases were associated with lower median age and male-to-female ratio. There was no statistically significant difference in the complete remission rate between both the subtypes. ETP-ALL was seen to be associated with high induction failure and relapse rate compared to non-ETP-ALL. To summarise, since the 2-year OS was poor compared to western research (for both ALLs), an intensive chemo-regimen should be implemented in the current situation. Some unusual markers were observed on flow-cytometry (ETP-ALL), which can be useful for MRD quantification, prognosis, and further trials for newer targeted therapies.

早期T细胞前体淋巴细胞白血病(ETP-ALL)具有独特的免疫表型,具有非常早期的T细胞分化。目前的研究总结了ETP-ALL的不同临床病理方面,并将其与非ETP-ALL进行了比较。2018年至2021年间,共检索到29例ETP-ALL和191例非ETP-ALL病例。确定每个患者特征的P值(表1),以查看任何显著关系(P
{"title":"A Comparative Analysis of Early T-Cell Precursor Lymphoblastic Leukemia/Lymphoma (ETP-ALL/LBL) and Non-ETP-ALL/LBL in a Tertiary Cancer Care Center Based in Western India.","authors":"Anurag Saha, Beena Brahmbhatt, Varnika Rai, Sneha Kakoty, Jyoti Sawhney","doi":"10.1007/s12288-023-01627-4","DOIUrl":"10.1007/s12288-023-01627-4","url":null,"abstract":"<p><p>Early T-cell precursor lymphoblastic leukemia (ETP-ALL) has a unique immunophenotype with very early T-cell differentiation. The current study summarises the distinct clinicopathological aspects of ETP-ALL and compares them with non-ETP-ALL. Twenty-nine ETP-ALL and 191 non-ETP-ALL cases were retrieved between 2018 and 2021. A <i>P</i> value was determined for each of the patient charaterisics (Table 1) to see for any significant relationship (<i>P</i> < 0.05) with ETP-ALL versus non-ETP-ALL. Kaplan-Meier log rank test was applied to look for any significant differences in OS for both the ALLs. ETP-ALL had an incidence of 12.6% out of total T-Acute lymphoblastic leukemia (T-ALL/LBL) in the past 3-years. Compared to non-ETP-ALL, ETP-ALL cases were associated with lower median age and male-to-female ratio. There was no statistically significant difference in the complete remission rate between both the subtypes. ETP-ALL was seen to be associated with high induction failure and relapse rate compared to non-ETP-ALL. To summarise, since the 2-year OS was poor compared to western research (for both ALLs), an intensive chemo-regimen should be implemented in the current situation. Some unusual markers were observed on flow-cytometry (ETP-ALL), which can be useful for MRD quantification, prognosis, and further trials for newer targeted therapies.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"39 4","pages":"699-704"},"PeriodicalIF":0.7,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542041/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41154222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Co-inherited α-Globin Gene Cluster Duplication Compromises RBC Indices-Based Thalassemia Screening. 共遗传α-球蛋白基因簇重复损害红细胞指数的地中海贫血筛查。
IF 0.7 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-10-01 Epub Date: 2022-11-04 DOI: 10.1007/s12288-022-01601-6
Huan-Qing Chen, Li-Sha Wu, Fan Jiang, Dong-Zhi Li
{"title":"Co-inherited α-Globin Gene Cluster Duplication Compromises RBC Indices-Based Thalassemia Screening.","authors":"Huan-Qing Chen, Li-Sha Wu, Fan Jiang, Dong-Zhi Li","doi":"10.1007/s12288-022-01601-6","DOIUrl":"10.1007/s12288-022-01601-6","url":null,"abstract":"","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"39 4","pages":"705-707"},"PeriodicalIF":0.7,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41155076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Conventional Gold Standard Techniques: Indeed a Saviour in the Era of Automation!! 传统金标准技术:自动化时代的救世主!!
IF 0.7 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-10-01 Epub Date: 2023-03-28 DOI: 10.1007/s12288-023-01644-3
Yashaswi Dhiman, Manish Raturi, Bhawana Adhikari, Himanshu Rawat, Dushyant Singh Gaur
{"title":"Conventional Gold Standard Techniques: Indeed a Saviour in the Era of Automation!!","authors":"Yashaswi Dhiman, Manish Raturi, Bhawana Adhikari, Himanshu Rawat, Dushyant Singh Gaur","doi":"10.1007/s12288-023-01644-3","DOIUrl":"10.1007/s12288-023-01644-3","url":null,"abstract":"","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"39 4","pages":"717-720"},"PeriodicalIF":0.7,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41148705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thyroid Dysfunction in Patients with and Without Venous Thromboembolism: a Case Control Study. 静脉血栓栓塞和非静脉血栓栓塞患者的甲状腺功能障碍:一项病例对照研究。
IF 0.7 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-10-01 Epub Date: 2023-04-17 DOI: 10.1007/s12288-023-01643-4
Rizwana Naushad, Jayachandran Selvaraj, Jayaprakash Sahoo, Stalin Viswanathan, Rajeswari Murugesan

Recent studies report an association between thyroid dysfunction and venous thromboembolism (VTE). Considering the high prevalence of thyroid diseases in India, identification of thyroid dysfunction as a risk factor for VTE will have implications in management. The aim of study was to determine if thyroid dysfunction could be considered as risk factor for unprovoked VTE. The study was conducted on 102 patients with unprovoked VTE and 102 age and gender matched controls in a tertiary care centre. Clinical profile and thyroid function tests (Free T3, Free T4, TSH) including antibody profile (Anti TPO and Anti TG) were compared between two groups. Thyroid disease was identified in 34 cases and 14 controls (33.1% vs. 13.7%, P = 0.001) Out of 34 cases with thyroid dysfunction, 17 had subclinical hypothyroidism (SCH) while 6 out of 14 controls had SCH. Both thyroid dysfunction and SCH were found to be associated with unprovoked VTE, as compared with controls; [Odds ratio (OR) = 3.14, 95% CI 1.56-6.33, P = 0.001] and (OR = 3.71; 95% CI 1.4-9.9; P = 0.01) respectively. Thyroid dysfunction was significantly higher among patients with unprovoked VTE. Thyroid dysfunction, SCH were associated with unprovoked VTE.

最近的研究报告了甲状腺功能障碍与静脉血栓栓塞症(VTE)之间的关系。考虑到印度甲状腺疾病的高患病率,将甲状腺功能障碍确定为VTE的风险因素将对管理产生影响。本研究的目的是确定甲状腺功能障碍是否可以被视为无端VTE的危险因素。这项研究在一家三级护理中心对102名无端VTE患者和102名年龄和性别匹配的对照组进行。比较两组的临床特征和甲状腺功能测试(游离T3、游离T4、TSH),包括抗体特征(抗TPO和抗TG)。在34例病例和14名对照组中发现了甲状腺疾病(33.1%对13.7%,P=0.001)。在34例甲状腺功能障碍病例中,17例患有亚临床甲状腺功能减退症(SCH),而14名对照中有6例患有SCH。与对照组相比,甲状腺功能障碍和SCH均与无端VTE有关;[比值比(OR) = 3.14,95%置信区间1.56-6.33,P = 0.001]和(OR = 3.71;95%置信区间1.4-9.9;P = 0.01)。在无端VTE患者中,甲状腺功能障碍明显更高。甲状腺功能障碍、SCH与无端VTE相关。
{"title":"Thyroid Dysfunction in Patients with and Without Venous Thromboembolism: a Case Control Study.","authors":"Rizwana Naushad, Jayachandran Selvaraj, Jayaprakash Sahoo, Stalin Viswanathan, Rajeswari Murugesan","doi":"10.1007/s12288-023-01643-4","DOIUrl":"10.1007/s12288-023-01643-4","url":null,"abstract":"<p><p>Recent studies report an association between thyroid dysfunction and venous thromboembolism (VTE). Considering the high prevalence of thyroid diseases in India, identification of thyroid dysfunction as a risk factor for VTE will have implications in management. The aim of study was to determine if thyroid dysfunction could be considered as risk factor for unprovoked VTE. The study was conducted on 102 patients with unprovoked VTE and 102 age and gender matched controls in a tertiary care centre. Clinical profile and thyroid function tests (Free T3, Free T4, TSH) including antibody profile (Anti TPO and Anti TG) were compared between two groups. Thyroid disease was identified in 34 cases and 14 controls (33.1% vs. 13.7%, <i>P</i> = 0.001) Out of 34 cases with thyroid dysfunction, 17 had subclinical hypothyroidism (SCH) while 6 out of 14 controls had SCH. Both thyroid dysfunction and SCH were found to be associated with unprovoked VTE, as compared with controls; [Odds ratio (OR) = 3.14, 95% CI 1.56-6.33, <i>P</i> = 0.001] and (OR = 3.71; 95% CI 1.4-9.9; <i>P</i> = 0.01) respectively. Thyroid dysfunction was significantly higher among patients with unprovoked VTE. Thyroid dysfunction, SCH were associated with unprovoked VTE.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"39 4","pages":"649-654"},"PeriodicalIF":0.7,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41155077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preconditioning Modified-Easix as a Predictor of Prognosis in Allogeneic Hematopoietic Stem Cell Transplant Recipients. 预处理改良Easix作为异基因造血干细胞移植受者预后的预测因子。
IF 0.7 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-10-01 Epub Date: 2023-01-04 DOI: 10.1007/s12288-022-01623-0
Zeynep Arzu Yegin, Emine Merve Savaş, Şeyma Yıldız, Münevver İrem Kök, Meltem Büşra Erdemir, Başak Bostankolu Değirmenci, Zübeyde Nur Özkurt, Münci Yağcı

Allogeneic hematopoietic stem cell transplantation (alloHCT) is associated with severe complications, most of which share a common physiopathological background characterized by endothelial dysfunction. A novel risk assessment model, endothelial activation and stress index (EASIX), has been introduced as a predictor of endothelial activation. This retrospective study was performed to evaluate the predictive impact of EASIX/modified-EASIX (mEASIX) on transplant outcome. Medical records of 398 alloHCT recipients [median age: 43(17-71) years; M/F: 243/155] were examined. EASIX/mEASIX were calculated at specific time points before and after transplantation. EASIX/mEASIX were significantly associated with transplant complications including engraftment syndrome, sinusoidal obstruction syndrome, febrile neutropenia and transplant associated thrombotic microangiopathy. The probability of overall survival was significantly higher in low-preconditioning mEASIX (day -7) group (37% vs 25.2%; p = 0.008; HR: 2.057; 95% CI: 1.208-3.504). The probabilities of day30 mortality (2.9% vs 19.4%; p = 0.017; HR: 7.028; 95% CI: 1.418-34.836), day100 mortality (9% vs 33%; p = 0.004; HR: 4.469; 95% CI: 1.619-12.336) and non relapse mortality (44.8% vs 61.4%; p = 0.005; HR: 2.551; 95% CI: 1.318-4.941) were lower in low-preconditioning mEASIX (day -7) group. This retrospective cohort analysis demonstrates the significant impact of EASIX/mEASIX on transplant complications and survival. Prospective analyses are mandatory to assess the predictive role of EASIX/mEASIX in clinical practice.

异基因造血干细胞移植(alloHCT)与严重并发症有关,其中大多数并发症具有以内皮功能障碍为特征的共同生理病理背景。一种新的风险评估模型,内皮细胞活化和应激指数(EASIX),已被引入作为内皮细胞活化的预测指标。本回顾性研究旨在评估EASIX/改良EASIX(mEASIX)对移植结果的预测影响。检查了398名同种异体HCT接受者的医疗记录[中位年龄:43(17-71)岁;男/女:243/155]。在移植前后的特定时间点计算EASIX/mEASIX。EASIX/mEASIX与移植并发症显著相关,包括植入综合征、窦梗阻综合征、发热性中性粒细胞减少症和移植相关血栓性微血管病。低预处理mEASIX(第7天)组的总生存概率显著较高(37%对25.2%;p = 0.008;小时:2.057;95%可信区间:1.208-3.504)。第30天死亡的概率(2.9%对19.4%;p = 0.017;小时:7.028;95%可信区间:1.418-34.836),第100天死亡率(9%对33%;p = 0.004;小时:4.469;95%可信区间:1.619-12.336)和无复发死亡率(44.8%vs 61.4%;p = 0.005;小时:2.551;95%可信区间1.318-4.941)较低。这项回顾性队列分析证明了EASIX/mEASIX对移植并发症和生存率的显著影响。前瞻性分析是强制性的,以评估EASIX/mEASIX在临床实践中的预测作用。
{"title":"Preconditioning Modified-Easix as a Predictor of Prognosis in Allogeneic Hematopoietic Stem Cell Transplant Recipients.","authors":"Zeynep Arzu Yegin, Emine Merve Savaş, Şeyma Yıldız, Münevver İrem Kök, Meltem Büşra Erdemir, Başak Bostankolu Değirmenci, Zübeyde Nur Özkurt, Münci Yağcı","doi":"10.1007/s12288-022-01623-0","DOIUrl":"10.1007/s12288-022-01623-0","url":null,"abstract":"<p><p>Allogeneic hematopoietic stem cell transplantation (alloHCT) is associated with severe complications, most of which share a common physiopathological background characterized by endothelial dysfunction. A novel risk assessment model, endothelial activation and stress index (EASIX), has been introduced as a predictor of endothelial activation. This retrospective study was performed to evaluate the predictive impact of EASIX/modified-EASIX (mEASIX) on transplant outcome. Medical records of 398 alloHCT recipients [median age: 43(17-71) years; M/F: 243/155] were examined. EASIX/mEASIX were calculated at specific time points before and after transplantation. EASIX/mEASIX were significantly associated with transplant complications including engraftment syndrome, sinusoidal obstruction syndrome, febrile neutropenia and transplant associated thrombotic microangiopathy. The probability of overall survival was significantly higher in low-preconditioning mEASIX (day -7) group (37% vs 25.2%; <i>p</i> = 0.008; HR: 2.057; 95% CI: 1.208-3.504). The probabilities of day30 mortality (2.9% vs 19.4%; <i>p</i> = 0.017; HR: 7.028; 95% CI: 1.418-34.836), day100 mortality (9% vs 33%; <i>p</i> = 0.004; HR: 4.469; 95% CI: 1.619-12.336) and non relapse mortality (44.8% vs 61.4%; <i>p</i> = 0.005; HR: 2.551; 95% CI: 1.318-4.941) were lower in low-preconditioning mEASIX (day -7) group. This retrospective cohort analysis demonstrates the significant impact of EASIX/mEASIX on transplant complications and survival. Prospective analyses are mandatory to assess the predictive role of EASIX/mEASIX in clinical practice.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"39 4","pages":"586-597"},"PeriodicalIF":0.7,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41160485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India. Nonacog Alfa用于预防和治疗印度既往治疗的中重度或重度血友病B患者的出血发作。
IF 0.9 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-10-01 Epub Date: 2022-11-27 DOI: 10.1007/s12288-022-01588-0
Nirmalkumar Choraria, Savita Rangarajan, M Joseph John, Shashikant Apte, Pritam Gupta, Seema Pai, Rohit Chand, Shyam Parvatini, G S H Ramakanth, Jeremy Rupon, Amit Chhabra, Hitesh Bhaskarrao Muley, Damien Simoneau

Purpose: Hemophilia B is an X-linked congenital bleeding disorder caused by a deficiency of coagulation factor IX (FIX) clotting activity. This study evaluated safety and efficacy of nonacog alfa, a recombinant human blood coagulation FIX replacement product, in males aged 12-65 years with hemophilia B (FIX activity ≤ 2%) with or without inhibitors in India.

Methods: In this multicenter, open-label, post-approval phase 4 study, participants were treated for up to 8 weeks, with up to a 4-week screening period and a subsequent post-treatment 28-day safety observation period. Intravenous nonacog alfa 40 IU/kg (range 13-78 IU/kg) was administered at intervals of 3-4 days, in accordance with the approved local product document.

Results: A total of 25 participants were enrolled and completed the study. No participants developed FIX inhibitors during the study, experienced treatment-related adverse events (AEs) or serious AEs, or developed a thrombotic event and/or hypersensitivity reaction. No participants experienced bleeding events requiring on-demand treatment with nonacog alfa. Seventeen bleeding episodes (16 spontaneous and 1 traumatic) were reported in 10 participants; all occurred post treatment, with the exception of a minor gum-bleeding event, and were managed without treatment. The mean (SD) annualized total factor consumption (TFC) per patient was 224,582 (75,527) IU; the mean (SD) annualized TFC by weight per patient was 3639 (573) IU/kg.

Conclusion: Nonacog alfa was safe and effective for the prevention of hemorrhagic episodes in Indian males with congenital, severe hemophilia B. No participants developed FIX inhibitors, and no new safety signals were reported.

目的:血友病B是一种由凝血因子IX(FIX)凝血活性缺乏引起的X连锁先天性出血性疾病。本研究评估了重组人凝血FIX替代品nonacog-alfa对12-65岁患有血友病B(FIX活性)的男性的安全性和有效性 ≤ 2%)。方法:在这项多中心、开放标签、批准后第4阶段研究中,参与者接受了长达8周的治疗,包括长达4周的筛查期和随后的28天治疗后安全观察期。根据批准的当地产品文件,每隔3-4天静脉注射40 IU/kg(范围13-78 IU/kg)的壬二酸阿尔法。结果:共有25名参与者入选并完成了研究。在研究期间,没有参与者出现FIX抑制剂,没有出现治疗相关不良事件(AE)或严重AE,也没有出现血栓事件和/或超敏反应。没有参与者出现需要按需使用非cog alfa治疗的出血事件。10名参与者报告了17次出血事件(16次为自发性出血,1次为创伤性出血);除轻微牙龈出血外,所有病例均发生在治疗后,均未经治疗。每位患者的年化总因子消耗(TFC)平均值为224582(75527)IU;每名患者的平均(SD)年化TFC(按体重计)为3639(573)IU/kg。结论:Nonacog-alfa对预防患有先天性严重血友病B的印度男性出血是安全有效的。没有参与者开发出FIX抑制剂,也没有新的安全信号报告。
{"title":"Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India.","authors":"Nirmalkumar Choraria,&nbsp;Savita Rangarajan,&nbsp;M Joseph John,&nbsp;Shashikant Apte,&nbsp;Pritam Gupta,&nbsp;Seema Pai,&nbsp;Rohit Chand,&nbsp;Shyam Parvatini,&nbsp;G S H Ramakanth,&nbsp;Jeremy Rupon,&nbsp;Amit Chhabra,&nbsp;Hitesh Bhaskarrao Muley,&nbsp;Damien Simoneau","doi":"10.1007/s12288-022-01588-0","DOIUrl":"https://doi.org/10.1007/s12288-022-01588-0","url":null,"abstract":"<p><strong>Purpose: </strong>Hemophilia B is an X-linked congenital bleeding disorder caused by a deficiency of coagulation factor IX (FIX) clotting activity. This study evaluated safety and efficacy of nonacog alfa, a recombinant human blood coagulation FIX replacement product, in males aged 12-65 years with hemophilia B (FIX activity ≤ 2%) with or without inhibitors in India.</p><p><strong>Methods: </strong>In this multicenter, open-label, post-approval phase 4 study, participants were treated for up to 8 weeks, with up to a 4-week screening period and a subsequent post-treatment 28-day safety observation period. Intravenous nonacog alfa 40 IU/kg (range 13-78 IU/kg) was administered at intervals of 3-4 days, in accordance with the approved local product document.</p><p><strong>Results: </strong>A total of 25 participants were enrolled and completed the study. No participants developed FIX inhibitors during the study, experienced treatment-related adverse events (AEs) or serious AEs, or developed a thrombotic event and/or hypersensitivity reaction. No participants experienced bleeding events requiring on-demand treatment with nonacog alfa. Seventeen bleeding episodes (16 spontaneous and 1 traumatic) were reported in 10 participants; all occurred post treatment, with the exception of a minor gum-bleeding event, and were managed without treatment. The mean (SD) annualized total factor consumption (TFC) per patient was 224,582 (75,527) IU; the mean (SD) annualized TFC by weight per patient was 3639 (573) IU/kg.</p><p><strong>Conclusion: </strong>Nonacog alfa was safe and effective for the prevention of hemorrhagic episodes in Indian males with congenital, severe hemophilia B. No participants developed FIX inhibitors, and no new safety signals were reported.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"39 4","pages":"630-634"},"PeriodicalIF":0.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41166417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High Autophagy Patterns in Swelling Platelets During Apheresis Platelet Storage. 单采血小板储存过程中膨胀血小板的高自噬模式。
IF 0.7 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-10-01 Epub Date: 2023-03-08 DOI: 10.1007/s12288-023-01638-1
Lu Yu, Shifang Yu, Yunlei He, Gang Deng, Qiang Li

Platelets undergo remarkable morphological changes during storage. Platelets change into different sizes and densities and differ in their biochemistry and functions. However, the correlation between structural heterogeneity and platelet autophagy is largely unknown. The aim of this study was to investigate the autophagy process in vitro, such as routine storage of platelets, and explore the role of reactive oxygen species (ROS) involved in the regulation of platelet autophagy. The ROS and autophagy levels of platelet concentrates from apheresis platelets were evaluated through flow cytometry. The expression levels of autophagy-associated proteins (LC3I, LC3II, Beclin1, Parkin, and PINK1) were measured via Western blot. All biomarkers were dynamically monitored for seven days. Moreover, the morphological characteristics of platelet morphology during storage were analyzed through transmission electron microscopy (TEM). Flow cytometry showed that the levels of total cell ROS and mitochondria ROS increased in the stored platelets. Together with the increase in mitochondrial ROS, the autophagy signal LC3 in the platelets was strongly amplified. The number of swollen platelets (large platelets) considerably increased, and that of autophagy signal LC3 was remarkably higher than that of the normal platelets. Western blot revealed that the expression levels of Beclin1 and LC3 II/LC3 I ratio were enhanced, whereas those of Parkin and PINK1 almost did not change during the seven days of storage. The existence of autophagosomes or autophagolysosomes in the platelets at the middle stage of platelet storage was observed via TEM. Our data demonstrated that the subpopulation of large (swollen) platelets exhibited different autophagy patterns. Furthermore, increased platelet autophagy was associated with mitochondrial ROS. These preliminary results suggest that swelling platelets have a higher autophagy pattern than normal platelets during storage.

血小板在储存过程中会发生显著的形态变化。血小板的大小和密度不同,其生物化学和功能也不同。然而,结构异质性与血小板自噬之间的相关性在很大程度上是未知的。本研究的目的是研究体外自噬过程,如血小板的常规储存,并探索活性氧(ROS)在血小板自噬调节中的作用。通过流式细胞术评估单采血小板浓缩物的ROS和自噬水平。通过蛋白质印迹测定自噬相关蛋白(LC3I、LC3II、Beclin1、Parkin和PINK1)的表达水平。对所有生物标志物进行为期7天的动态监测。此外,通过透射电子显微镜(TEM)分析了血小板在储存过程中的形态特征。流式细胞术显示,储存的血小板中总细胞ROS和线粒体ROS水平增加。随着线粒体ROS的增加,血小板中的自噬信号LC3被强烈放大。肿胀的血小板(大血小板)的数量显著增加,自噬信号LC3的数量显著高于正常血小板。蛋白质印迹显示,Beclin1和LC3 II/LC3 I的表达水平提高,而Parkin和PINK1的表达水平在储存的7天内几乎没有变化。通过TEM观察血小板储存中期血小板中存在自噬体或自噬多体。我们的数据表明,大(肿胀)血小板的亚群表现出不同的自噬模式。此外,血小板自噬增加与线粒体ROS有关。这些初步结果表明,膨胀的血小板在储存过程中比正常血小板具有更高的自噬模式。
{"title":"High Autophagy Patterns in Swelling Platelets During Apheresis Platelet Storage.","authors":"Lu Yu, Shifang Yu, Yunlei He, Gang Deng, Qiang Li","doi":"10.1007/s12288-023-01638-1","DOIUrl":"10.1007/s12288-023-01638-1","url":null,"abstract":"<p><p>Platelets undergo remarkable morphological changes during storage. Platelets change into different sizes and densities and differ in their biochemistry and functions. However, the correlation between structural heterogeneity and platelet autophagy is largely unknown. The aim of this study was to investigate the autophagy process in vitro, such as routine storage of platelets, and explore the role of reactive oxygen species (ROS) involved in the regulation of platelet autophagy. The ROS and autophagy levels of platelet concentrates from apheresis platelets were evaluated through flow cytometry. The expression levels of autophagy-associated proteins (LC3I, LC3II, Beclin1, Parkin, and PINK1) were measured via Western blot. All biomarkers were dynamically monitored for seven days. Moreover, the morphological characteristics of platelet morphology during storage were analyzed through transmission electron microscopy (TEM). Flow cytometry showed that the levels of total cell ROS and mitochondria ROS increased in the stored platelets. Together with the increase in mitochondrial ROS, the autophagy signal LC3 in the platelets was strongly amplified. The number of swollen platelets (large platelets) considerably increased, and that of autophagy signal LC3 was remarkably higher than that of the normal platelets. Western blot revealed that the expression levels of Beclin1 and LC3 II/LC3 I ratio were enhanced, whereas those of Parkin and PINK1 almost did not change during the seven days of storage. The existence of autophagosomes or autophagolysosomes in the platelets at the middle stage of platelet storage was observed via TEM. Our data demonstrated that the subpopulation of large (swollen) platelets exhibited different autophagy patterns. Furthermore, increased platelet autophagy was associated with mitochondrial ROS. These preliminary results suggest that swelling platelets have a higher autophagy pattern than normal platelets during storage.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"39 4","pages":"670-678"},"PeriodicalIF":0.7,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41167425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The utility of quantitative D-Dimer assay as a biomarker in the diagnosis and exclusion of Cerebral Venous Sinus Thrombosis 定量d -二聚体测定在脑静脉窦血栓形成诊断和排除中的应用
IF 0.9 4区 医学 Q4 HEMATOLOGY Pub Date : 2022-12-22 DOI: 10.1101/2022.12.21.22283814
Dipesh Soni, A. Pannu, A. Saroch, V. Bhatia, J. Ahluwalia, Rajveer Singh, Arihant Jain
Thrombotic disorders are characterized by the presence of elevated levels of detectable fibrin degradation products in the blood. The utility and sensitivity of quantitative D-Dimer assay to rule out the diagnosis of deep vein thrombosis is well established. We extrapolated this principle to evaluate the utility of D-Dimer assay in exclusion of cerebral venous sinus thrombosis (CVST). CVST is an important cause of cerebrovascular accidents in young patients and the residual neurological deficits can be minimized if correct therapy, i.e., anticoagulation is instituted in a timely manner. As advanced imaging modalities that are required for the diagnosis of CVST might not be readily available everywhere, it is important to have a sensitive biomarker which can guide clinicians to rule out the diagnosis with a reasonable confidence. We evaluated the patients admitted at a tertiary care center who underwent Computed tomography (CT) Venography/Magnetic resonance (MR) Venography of the brain with the clinical suspicion of CVST. After appropriate exclusion, a quantitative D-Dimer assay was performed in patients who had CVST on CT/MR Venography and was compared with those patients who did not. Receiver operating characteristic (ROC) analysis revealed that quantitative D Dimer had poor diagnostic accuracy for the differentiation of CVST from non CVST cases (Area under the curve = 0.694), but D-Dimer levels of <300 ng/mL had a sensitivity of 90% for ruling out the diagnosis of CVST.
血栓性疾病的特点是血液中可检测到的纤维蛋白降解产物水平升高。定量d -二聚体测定排除深静脉血栓诊断的实用性和敏感性已得到充分证实。我们推断这一原则来评估d -二聚体测定在排除脑静脉窦血栓形成(CVST)方面的效用。CVST是年轻患者发生脑血管意外的重要原因,如果及时进行正确的治疗,如抗凝治疗,可以减少残余的神经功能缺损。由于诊断CVST所需的先进成像模式可能并非随处可见,因此有一种敏感的生物标志物可以指导临床医生以合理的信心排除诊断是很重要的。我们评估了在三级保健中心接受计算机断层扫描(CT)静脉造影/磁共振(MR)静脉造影的临床怀疑为CVST的患者。在适当的排除后,对CT/MR静脉造影有CVST的患者进行定量d -二聚体测定,并与没有CVST的患者进行比较。受试者工作特征(ROC)分析显示,定量D-二聚体对CVST与非CVST的鉴别诊断准确性较差(曲线下面积= 0.694),但D-二聚体水平<300 ng/mL对排除CVST诊断的敏感性为90%。
{"title":"The utility of quantitative D-Dimer assay as a biomarker in the diagnosis and exclusion of Cerebral Venous Sinus Thrombosis","authors":"Dipesh Soni, A. Pannu, A. Saroch, V. Bhatia, J. Ahluwalia, Rajveer Singh, Arihant Jain","doi":"10.1101/2022.12.21.22283814","DOIUrl":"https://doi.org/10.1101/2022.12.21.22283814","url":null,"abstract":"Thrombotic disorders are characterized by the presence of elevated levels of detectable fibrin degradation products in the blood. The utility and sensitivity of quantitative D-Dimer assay to rule out the diagnosis of deep vein thrombosis is well established. We extrapolated this principle to evaluate the utility of D-Dimer assay in exclusion of cerebral venous sinus thrombosis (CVST). CVST is an important cause of cerebrovascular accidents in young patients and the residual neurological deficits can be minimized if correct therapy, i.e., anticoagulation is instituted in a timely manner. As advanced imaging modalities that are required for the diagnosis of CVST might not be readily available everywhere, it is important to have a sensitive biomarker which can guide clinicians to rule out the diagnosis with a reasonable confidence. We evaluated the patients admitted at a tertiary care center who underwent Computed tomography (CT) Venography/Magnetic resonance (MR) Venography of the brain with the clinical suspicion of CVST. After appropriate exclusion, a quantitative D-Dimer assay was performed in patients who had CVST on CT/MR Venography and was compared with those patients who did not. Receiver operating characteristic (ROC) analysis revealed that quantitative D Dimer had poor diagnostic accuracy for the differentiation of CVST from non CVST cases (Area under the curve = 0.694), but D-Dimer levels of <300 ng/mL had a sensitivity of 90% for ruling out the diagnosis of CVST.","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"1 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48291485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Indian Journal of Hematology and Blood Transfusion
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1